CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 105 enrolled
Drug / intervention
Freezor® Cardiac Cryoablation Catheter CryoConsole Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621621
NCT00621621Phase 4Completed
CompareCT.gov

CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Feb 22, 2008·Updated Oct 16, 2018

In Brief

A Phase 4 clinical trial evaluating Freezor® Cardiac Cryoablation Catheter CryoConsole System for Tachycardia, Atrioventricular Nodal Reentry. Completed, enrolled 105 participants across 4 sites.

Detailed Summary

The purpose of this post approval study of heart block is to gather additional information regarding how often patients develop heart block (atrioventricular block) after having standard ablation procedure using cryotherapy with the Freezor™ catheter.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTachycardia, Atrioventricular Nodal Reentry
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 18.4 years ago

Interventions

Freezor® Cardiac Cryoablation Catheter CryoConsole Systemdevice

cryoablation